Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients

NCT01889407 · clinicaltrials.gov ↗

UNKNOWN

Status

94

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Idarubicin

Sponsor

Nanfang Hospital, Southern Medical University

Collaborators

[object Object]